Lord, Abbett & Co
AKRO

Lord, Abbett & Co’s Akero Therapeutics AKRO Stock Holding History

Lord, Abbett & Co’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-527,004
Closed -$21.3M – 510
2025
Q1 		$21.3M Buy
+527,004
New +$22.3M 0.08% 280
2023
Q4 		– Sell
-779,126
Closed -$39.4M – 514
2023
Q3 		$39.4M Buy
779,126
+472,898
+154% +$22M 0.15% 199
2023
Q2 		$14.3M Buy
+306,228
New +$14M 0.05% 386

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's AKRO Position: Q2 2025 in Review

Lord, Abbett & Co sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 527,004 shares — an estimated $21.3M sold.

Lord, Abbett & Co first reported a position in AKRO in Q2 2023 and held it in 3 quarters. The position peaked at $39.4M in Q3 2023. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • Lord, Abbett & Co reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 527,004 Akero Therapeutics shares in Q2 2025, an estimated $21.3M.
  • Lord, Abbett & Co first reported a position in Akero Therapeutics in Q2 2023 and held it in 3 quarters.
  • Lord, Abbett & Co's Akero Therapeutics position peaked at $39.4M in Q3 2023.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Lord, Abbett & Co's 13F filing for Q2 2025, filed 14 Aug 2025.